A Multicenter, Open-Label, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib (E7080) Versus Sorafenib in First-line Treatment of Participants With Unresectable Hepatocellular Carcinoma
Open the official record
This page only displays public information reproduced from the official ClinicalTrials.gov record NCT01761266. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Multicenter, Randomized, Open-Label, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib (E7080) Versus Sorafenib in First-Line Treatment of Subjects With Unresectable Hepatocellular Carcinoma
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
E7080-G000-304 is a multicenter, randomized, open-label, noninferiority Phase 3 study to compare the efficacy and safety of lenvatinib versus sorafenib as a first-line systemic treatment in participants with unresectable Hepatocellular Carcinoma (HCC).
Study identification
- NCT ID
- NCT01761266
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 954 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 1, 2013 (Actual)
- Primary completion
- Nov 13, 2016 (Actual)
- Completion
- Mar 10, 2021 (Actual)
- Last update posted
- Apr 5, 2022
2013 – 2021
United States locations
- U.S. sites
- 21
- U.S. states
- 13
- U.S. cities
- 21
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Facility # 1 | Los Angeles | California | — | — |
| Facility # 1 | Sacramento | California | — | — |
| Facility # 1 | San Francisco | California | — | — |
| Facility # 1 | Washington D.C. | District of Columbia | — | — |
| Facility # 1 | Tampa | Florida | — | — |
| Facility # 1 | Duluth | Georgia | — | — |
| Facility # 1 | Lawrenceville | Georgia | — | — |
| Facility # 1 | Baltimore | Maryland | — | — |
| Facility # 1 | Detroit | Michigan | — | — |
| Facility # 1 | Kansas City | Missouri | — | — |
| Facility # 1 | St Louis | Missouri | — | — |
| Facility # 1 | East Orange | New Jersey | — | — |
| Facility # 1 | Brooklyn | New York | — | — |
| Facility # 1 | Lake Success | New York | — | — |
| Facility # 1 | New York | New York | — | — |
| Facility # 1 | Charlotte | North Carolina | — | — |
| Facility # 1 | Durham | North Carolina | — | — |
| Facility # 1 | Portland | Oregon | — | — |
| Facility # 1 | Austin | Texas | — | — |
| Facility # 1 | Lubbock | Texas | — | — |
| Facility # 1 | Seattle | Washington | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 165 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01761266, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 5, 2022 · Synced Nov 12, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.